Companies To Watch
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
Companies To Watch: Corner Therapeutics
Corner Therapeutics is focused on discovering new small molecules that could mimic the body’s natural immune response to generate the robust T-cell response.
Companies To Watch: Ocelot Bio
Ocelot Bio is focusing a single drug on multiple complications of end-stage liver disease.
Companies To Watch: iTolerance
iTolerance is dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation.
Companies To Watch: CytoAgents
CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.
Companies To Watch: Viking Therapeutics
Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.
Companies To Watch: Priothera
Priothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.
Companies To Watch: Mirum Pharmaceuticals
Mirum Pharmaceuticals: Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases.
Companies To Watch: CinCor Pharma
CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.
Companies To Watch: Castle Creek Biosciences
For Castle Creek Biosciences, there are many stakes at play in targeting rare skin, connective tissue, liver, and metabolic disorders.
Companies To Watch: Global Blood Therapeutics
Global Blood Therapeutics is intertwining science, business, and social missions to make progress against sickle cell disease.
Companies To Watch: Endevica Bio
Endevica Bio is developing a new treatment for cachexia, a severe wasting disease critical to patients’ survival in cancer and other conditions.
Companies To Watch: MiroBio
MiroBio is precisely targeting checkpoint receptors with agonist antibodies for better treatments in autoimmunity.
Companies To Watch: Qlaris Bio
Qlaris Bio is striking at an unaddressed target in the intraocular pressure of glaucoma.
Companies To Watch: Graphite Bio
Graphite Bio focuses on precise repair of genes that cause sickness, starting with Sickle Cell Disease.
BEYOND THE PRINTED PAGE
2023 Manufacturing And Supply Chain Outlook: Additional Insights12/16/2022
Additional executive responses to our 2023 manufacturing and supply chain outlook questions.
2023 Finance And Funding Outlook: Additional Insights Part 212/9/2022
Additional experts weigh in on Life Science Leader's 2023 finance and funding outlook questions.
2023 Finance And Funding Outlook: Additional Insights Part 112/2/2022
Biopharma executives offer options, tips and strategies for navigating finance and funding challenges in 2023.